BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

Luzah, since they reduced outstanding shares proportionally the $60 pps would equal a market cap of approx. $573 million.

Akorn, Przybyl's former company has a market cap of $1.29 billion with $256 million in annual revenue. Everything being equal if ANI gets their revenue up to $114 million you could break even.

ANI alone projected revenue of $147.4 million for 2017. This does not include any revenue from Bio-t-gel, Elestrin, Biosante or the Pill plus. Nor does it include any revenue from manufacturing Biosante's pipeline.

ANI's projected Revenue to EBITDA ratio is very similar, however once Biosante's pipeline starts generating revenue this will increase the company's revenue with little expense which should increase the PPS and require less revenue to get to $60. Not to mention that they have $10 million to shop for additional product product.

It should also be noted that management performance bonuses are directly tied to Revenues and EBITDA

The Board furthermore approved the Company’s annual management bonus program for 2013. Under this program, the target bonuses, as a percentage of base compensation, for the Company’s executive officers are as follows: Mr. Przybyl: 50%, Ms. Arnold: 40%, Mr. Marken: 30% and Mr. Jamnick: 30%. Performance targets for all executive officers are based on revenue and EBITDA.

If New Management really wants to make a go of ANI, $60 pps is very doable over the next 2 years, if not sooner.